CBD in the UK: Novel Food Rules, Authorisations and What Retailers Need to Know

Last reviewed: October 2026

CBD has become a familiar ingredient in the UK wellness market, appearing in oils, capsules, drinks and other consumer products. However, selling CBD is not simply a matter of sourcing an ingredient, designing a label and opening an online shop. Businesses must understand food safety rules, novel food authorisation, labelling requirements and restrictions on health claims.

The CBD novel food rules UK retailers need to understand are especially important in 2026, as regulators move towards decisions on the first applications for certain high-purity CBD ingredients. This is a significant development, but it does not mean that every CBD product currently available is automatically authorised.

This guide explains how the rules work, what the latest regulatory developments mean, how retailers can check products and which compliance questions deserve attention before a product is listed for sale.

What Are the UK CBD Novel Food Rules?

A novel food is generally a food that was not consumed to a significant degree in the UK or European Union before 15 May 1997. Novel foods must go through the relevant authorisation process before they can legally be placed on the market.

The Food Standards Agency (FSA) confirmed the novel food status of CBD in January 2019. CBD extracts, isolates, synthetic CBD and foods containing these ingredients are generally treated as novel foods when intended for consumption.

This means a CBD oil marketed as a food supplement cannot be assumed to be legal for sale simply because its ingredients are listed on the packaging or because similar products are sold elsewhere.

The distinction matters for manufacturers, importers, wholesalers, online sellers and retailers. Each business must understand its own responsibilities and verify that the products it supplies comply with the rules that apply to its market.

Official guidance is available through the GOV.UK cannabidiol (CBD) guidance.

Why Is CBD Classified as a Novel Food?

CBD extracts and isolates are produced through extraction, separation or other processing methods that can create ingredients different from traditional hemp foods. Regulators therefore require evidence that the ingredient is safe for its proposed uses.

A novel food application normally includes information about the ingredient’s identity, manufacturing process, composition, proposed uses, exposure levels and safety evidence. Regulators assess the evidence before ministers make the relevant authorisation decision.

An application being submitted or validated is not the same as receiving final authorisation. A product linked to an application may have a different regulatory status from a product covered by a completed authorisation.

Retailers should also distinguish CBD extracts from traditional hemp foods. Hemp seeds, hemp seed oil, ground hemp seeds and partially defatted hemp seeds have a demonstrated history of consumption and are not generally classed as novel on that basis. This does not mean every product derived from hemp is exempt.

CBD Authorisation in 2026: What Has Changed?

One of the most important developments in the CBD novel food rules UK market is the progress made on the first high-purity CBD applications.

In September 2026, the FSA published recommendations concerning three applications: synthetic CBD, CBD isolate and isolated CBD derived from hemp. The FSA and Food Standards Scotland had published positive safety opinions for these ingredients under their proposed conditions of use. The recommendations included restrictions and consumer-protection measures.

However, the distinction between a positive safety opinion, a recommendation and a final authorisation remains essential. The September 2026 government paper stated that ministers would make the final decisions. Retailers should therefore check the official authorisation register for the current outcome rather than assuming the applications have automatically been approved.

If an ingredient is authorised, the authorisation will apply according to its specific terms. These may define the ingredient’s specifications, permitted uses, maximum levels, labelling requirements and other conditions. An authorisation for one ingredient does not automatically authorise every CBD extract, formulation or product sold under a similar name.

For official updates, consult the FSA’s September 2026 recommendations on the first CBD authorisations.

What Is the FSA CBD Public List?

The FSA maintains a public list of CBD food products linked to novel food applications. The list is a useful starting point for retailers checking the status of an existing product.

According to the published criteria, the list covers products that were on the market by 13 February 2020, had an authorisation application submitted before 31 March 2021 and met the FSA’s relevant application-progress criteria.

For England and Wales, the FSA has recommended that products marked Validated or Awaiting evidence may remain on the market pending further consideration. Products marked Removed, or products that do not appear on the list, should not be treated as eligible under this interim arrangement.

Importantly, the FSA states that the list is not an endorsement of the products. Being listed does not mean that a product has completed the novel food authorisation process or received a final safety approval.

Retailers should search the official FSA CBD product list using the product name, manufacturer or supplier details. They should then check the current status and confirm that the listing actually covers the product being sold.

Do not rely exclusively on a supplier’s statement that its CBD product is compliant. Ask for the exact listing and supporting documentation, and independently verify the information.

What CBD Retailers Should Check Before Selling a Product

A consistent product-verification process can help retailers identify problems before products reach customers.

1. Verify the exact product

Check the brand, product name, formulation, manufacturer and supplier. Similar packaging or a shared brand name does not prove that two formulations have the same regulatory status.

2. Check the application or authorisation

If relying on the FSA Public List, verify the exact entry and its status. If relying on a final authorisation, check the official register and confirm that the ingredient and proposed use match the authorisation terms.

3. Request complete product documentation

Ask suppliers for ingredient specifications, manufacturing details, certificates of analysis where appropriate, batch information and relevant safety documentation. These records support due diligence but do not replace legal authorisation.

4. Review labels and product descriptions

Check that the label identifies the responsible business, gives accurate ingredient information and states the CBD amount clearly. Confirm that all mandatory warnings and other labelling requirements applicable to the product are met.

5. Keep records

Maintain copies of supplier documentation, product-list checks, batch records, label approvals and correspondence. Recheck products when suppliers change their formulation or when regulatory guidance is updated.

Retailers should also consider the rules that apply to importing, storing, advertising and distributing products. Compliance with novel food requirements does not automatically resolve every other legal obligation.

CBD Labelling and Consumer Safety

Labelling is a core part of CBD compliance. Consumers need clear information about what a product contains, how much CBD it provides and who should avoid using it.

The FSA’s published advice is that healthy adults should not consume more than 10 mg of CBD per day. This is a provisional acceptable daily intake recommendation, not a guarantee that CBD is safe for everyone or that a product is authorised for sale.

The FSA advises children under 18, people who are pregnant or breastfeeding, people trying to conceive and people taking medication to avoid CBD. People who are immunosuppressed are also included in the proposed warning approach for the first authorisations. Consumers taking medication should consult a healthcare professional about potential interactions.

Retailers should check the current official guidance and the terms of any relevant authorisation for precise labelling requirements. Do not assume that a warning copied from another product is sufficient for every formulation.

The FSA’s CBD safety and health claims guidance provides additional information on consumer advice and product claims.

Can CBD Products Make Health Claims?

CBD retailers should be cautious about language suggesting that a food or supplement treats, prevents or cures a medical condition.

Claims that a CBD oil treats anxiety, relieves chronic pain, cures insomnia or manages another disease can create serious regulatory problems. Food products may only use nutrition and health claims permitted under the relevant rules, and the FSA’s September 2026 recommendations state that there are no authorised health claims for CBD products.

A disclaimer does not automatically make a medicinal claim acceptable. The overall presentation of a product matters, including its product page, packaging, advertisements, testimonials and social media content.

CBD products marketed for medical purposes may fall under medicines legislation. The Medicines and Healthcare products Regulatory Agency explains that products presented with medicinal claims may require a marketing authorisation.

For retailers, the safer approach is to use accurate, evidence-based product information, avoid unsupported therapeutic promises and seek specialist regulatory advice if a claim’s status is uncertain.

Do the Rules Differ Across the UK?

Retailers must pay attention to geographical differences rather than treating the UK as one completely uniform market.

The FSA Public List discussed above applies to England and Wales. Scotland has its own food standards arrangements through Food Standards Scotland. Northern Ireland follows the relevant EU novel food framework for CBD food products, and the European Commission has not authorised CBD food products under that framework according to the published UK guidance.

This means a product’s status in one part of the UK should not automatically be taken as proof that it can be sold under the same conditions everywhere else.

Businesses selling online should consider where the product will be supplied, how it will be imported or distributed and which regulatory regime applies. If operating across Great Britain and Northern Ireland, obtain advice specific to each market and check the applicable official registers.

What Could Happen Next?

The CBD market is moving towards a more formal authorisation framework, but the transition requires careful attention from businesses.

The first high-purity applications could help establish how authorisation conditions are applied in practice. These conditions may cover ingredient specifications, permitted food categories, intake advice, warning statements and limits for THC and other controlled cannabinoids.

Further applications may progress at different speeds because each ingredient and formulation needs its own assessment. Businesses should not assume that a decision concerning one isolate or synthetic ingredient will cover broad-spectrum extracts, full-spectrum oils or other products.

Retailers should monitor official announcements, check the register regularly and review their supplier documentation whenever a product’s regulatory status changes. They should also prepare for updates to labelling, product information and enforcement guidance.

The practical priority is straightforward: verify every product, keep records and distinguish clearly between an application in progress and a final authorisation.

How CBD Compliance Fits into the Wider Hemp Market

CBD regulation is part of a broader conversation about hemp, consumer safety and responsible product development. Different hemp-derived products can fall under different legal frameworks depending on their ingredients, processing methods and intended use.

For readers exploring the wider market, DANK DISTRICT also provides related category pages for Cannabis Flower, Concentrates, Live Rosin, Top Shelf and Connoisseur Shelf.

These links are for browsing related categories; they should not be interpreted as a statement that any particular product is a CBD food or has novel food authorisation.

Conclusion: Understanding CBD Novel Food Rules in the UK

The CBD novel food rules UK businesses face are designed to ensure that CBD food ingredients undergo appropriate safety assessment before being authorised for sale. The progress made on the first high-purity applications in 2026 is an important regulatory development, but retailers must distinguish between safety opinions, recommendations, interim Public List arrangements and final authorisations.

Before selling a CBD product, verify its exact status, check the applicable register, review its labelling and claims, obtain reliable supplier documentation and keep records of your checks. Remember that requirements can differ between England, Wales, Scotland and Northern Ireland.

As the market evolves, businesses that follow official updates and prioritise transparent product information will be better placed to respond to regulatory changes. For retailers, manufacturers and consumers alike, informed decisions and careful verification remain essential to building a safer and more accountable UK CBD market.

Editorial note: This article is for general information and is not legal advice. Always check the latest official guidance and obtain specialist advice where necessary.

Understanding the CBD novel food rules UK retailers must follow is essential for businesses operating in the evolving CBD market. The CBD novel food rules UK framework requires businesses to distinguish between products linked to pending applications, products covered by interim arrangements and ingredients that have received final authorisation.

For retailers, the CBD novel food rules UK requirements begin with checking official records, verifying suppliers and reviewing product documentation. Businesses should also ensure that labels accurately describe ingredients, quantities and applicable warnings. Following the CBD novel food rules UK guidance helps businesses understand their responsibilities, although compliance must be assessed for each individual product.

The Food Standards Agency provides important information about the CBD novel food rules UK through its official CBD guidance and CBD product list. Retailers should monitor these resources for regulatory developments and verify any claimed authorisation before listing products.

Businesses should also avoid unauthorised medical claims and check the rules that apply across England, Wales, Scotland and Northern Ireland. Ultimately, understanding the CBD novel food rules UK framework, maintaining accurate records and prioritising consumer safety can help businesses make informed decisions as the market develops.

For further reading, explore DANK DISTRICT’s Cannabis Flower and Concentrates categories.

In conclusion, understanding the CBD novel food rules UK retailers must follow is essential for compliance and consumer safety. Businesses should verify product authorisations, check the FSA CBD product list and follow official UK CBD guidance. Staying informed about regulatory changes, maintaining accurate records and using responsible product descriptions will help retailers navigate the evolving UK CBD market with greater confidence.